The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. Contributors - p. Cover 6. Forthcoming Issues - p. Cover 7. Erratum - p. Cover 8. Preface. Cutaneous Lymphoma - p. Cover 9. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma - p. Cover 10. Pathologic Diagnosis of Cutaneous Lymphomas - p. Cover 11. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma - p. Cover 12. Phototherapy of Mycosis Fungoides - p. Cover 13. Radiation Therapy for Cutaneous T-Cell Lymphomas - p. Cover 14. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma - p. Cover 15. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma - p. Cover 16. Methotrexate and Pralatrexate - p. Cover 17. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma - p. Cover 18. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome - p. Cover 19. Monoclonal Antibodies - p. Cover 20. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma - p. Cover 21. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome - p. Cover 22. Practical Management of CD30+ Lymphoproliferative Disorders - p. Cover 23. Diagnosis and Management of Cutaneous B-cell Lymphoma - p. Cover 24. Index - p. Cover
No hay muestra disponible
No hay ficha técnica disponible
The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. Contributors - p. Cover 6. Forthcoming Issues - p. Cover 7. Erratum - p. Cover 8. Preface. Cutaneous Lymphoma - p. Cover 9. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma - p. Cover 10. Pathologic Diagnosis of Cutaneous Lymphomas - p. Cover 11. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma - p. Cover 12. Phototherapy of Mycosis Fungoides - p. Cover 13. Radiation Therapy for Cutaneous T-Cell Lymphomas - p. Cover 14. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma - p. Cover 15. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma - p. Cover 16. Methotrexate and Pralatrexate - p. Cover 17. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma - p. Cover 18. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome - p. Cover 19. Monoclonal Antibodies - p. Cover 20. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma - p. Cover 21. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome - p. Cover 22. Practical Management of CD30+ Lymphoproliferative Disorders - p. Cover 23. Diagnosis and Management of Cutaneous B-cell Lymphoma - p. Cover 24. Index - p. Cover
No hay muestra disponible
No hay ficha técnica disponible
